Safety and efficacy of topical finasteride nanoemulgel 0.25% in the treatment of mild to moderate androgenetic alopecia

Phase 2

Recruiting

• Conditions: hair loss.; Nonscarring hair loss, unspecified; L65.9

• Registration Number: IRCT20190210042676N22
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 May 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Male or female aged 20-50 years
Hair Loss Status II, III, IV Based on Norwood Scale for men
Hair Loss Status I,II Based on Ludwick Scale for women
General health
Voluntary participation and signing written informed consent

Exclusion Criteria

Chronic active scalp disease other than hair loss
Using any prescribed drug or over-the-counter(OTC) for hair loss within the past 3 months
Women with abnormal hormonal tests
Women with Polycystic ovary(PCO)
pregnancy or lactating women

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hair count changes. Timepoint: Before intervention, 2, 4 and 6 months after the start of treatment. Method of measurement: Trichoscopy by Fotofinder.

Secondary Outcome Measures

Name	Time	Method
Changes in the ratio of anagen to telogen hair. Timepoint: Before intervention, 2, 4 and 6 months after the start of treatment. Method of measurement: Trichoscopy by Fotofinder.